| ［1］ |
李慧, 杨宇. 免疫检查点抑制剂常见免疫相关不良反应及其管理［J］. 国际肿瘤学杂志, 2021,48（2）:105⁃108. doi: 10.3760/cma.j.cn371439⁃20200828⁃00020.
|
| ［2］ |
Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune⁃related adverse events from cancer immunotherapy［J］. Nat Rev Rheumatol, 2018,14（10）:569⁃579. doi: 10.1038/s41584⁃018⁃0074⁃9.
|
| ［3］ |
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper［J］. Ann Oncol, 2016,27（4）:559⁃574. doi: 10.1093/annonc/mdv623
|
| ［4］ |
Michot JM, Bigenwald C, Champiat S, et al. Immune⁃related adverse events with immune checkpoint blockade: a comprehensive review［J］. Eur J Cancer, 2016,54:139⁃148. doi: 10.1016/j.ejca.2015.11.016
|
| ［5］ |
Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow⁃up［J］. Ann Oncol, 2017,28（suppl_4）:iv119⁃119iv142. doi: 10.1093/annonc/mdx225.
|
| ［6］ |
姚卓然, 周潇翔, 杨华夏. 免疫检查点抑制剂所致风湿病样不良反应的发病机制临床特点及研究进展［J］. 中华风湿病学杂志, 2019,23（10）:699⁃702. doi: 10.3760/cma.j.issn.1007⁃7480. 2019.10.013.
|
